E-Submission
Yeungnam University College of MedicineIndexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
Search
- Page Path
- HOME > Search
Case report
- Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
- Jin Ho Baek
- J Yeungnam Med Sci. 2022;39(1):62-66. Published online April 19, 2021
- DOI: https://doi.org/10.12701/yujm.2021.00934
- 5,180 View
- 102 Download
- 3 Web of Science
- 4 Crossref
-
Abstract
PDF - Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.
-
Citations
Citations to this article as recorded by
- Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature
Yisi Deng, Manling Huang, Runpei Deng, Jun Wang
Medicine.2024; 103(12): e37562. CrossRef - Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
Frontiers in Oncology.2023;[Epub] CrossRef - Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
Qihao Zhou, Zhiquan Qin, Peiyuan Yan, Qunjiang Wang, Jing Qu, Yun Chen
Frontiers in Immunology.2023;[Epub] CrossRef - Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review
Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu
Frontiers in Oncology.2022;[Epub] CrossRef
- Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature
First
Prev
